Vigencell

Developer of T-cell therapy for tumour development

placeSeoul, Seoul, South Korea calendar_todayFounded 2013 groups80 employees language vigencell.com

Innovation

5 patent families — focus: Chemistry & metallurgy, Human necessities; filing pace steady. Cited 38 times.

YearFilings
20223
20231
20242
20251
20261

Investor mix

4 investors on record.

Investor typeCountShare
Venture capital125%
Private equity375%
Coming soon